Announcement on the 2020 profit distribution plan.
Release time:
2021-05-20
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Pro 2021-007
Zhejiang Jianfeng Group Co., Ltd.
Announcement on 2020 Profit Distribution Plan
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Important Content Note:
- Distribution Ratio per Share: Cash Dividend 4.0 Yuan (Including Tax) for Every 10 Shares. No bonus shares will be distributed in 2020, and no CPF capitalization will be carried out.
- This profit distribution is based on the total share capital registered on the equity registration date of the implementation of the equity distribution, and the specific date will be specified in the equity distribution implementation announcement.
- If the total share capital of the company changes before the equity registration date for the implementation of the equity distribution, it is proposed to maintain the distribution ratio per share unchanged and adjust the total distribution accordingly, and the specific adjustment will be announced separately.
- Brief description of this year's profit distribution plan: At present, the company is in the stage of accelerated development. In 2021, the company will continue to promote the peak pharmaceutical Jinxi production base annual output of 2 billion pieces of solid preparations project. In addition, Spike Pharmaceuticals and its subsidiaries have a number of new drugs in various stages of research and development, anti-tumor new drugs DPT and JFAN-1001 have entered the clinical stage, Spike Pharmaceuticals and its subsidiaries Zhejiang Erying, Spike Yien will further increase product research and development and introduction efforts, the need to increase investment in research and development. In addition, the company will continue to seek other development projects in cement and medicine. The development of the above-mentioned business requires large financial support.
Content of 1. Profit Distribution Plan
Audited by Tianjian Certified Public Accountants (Special General Partnership), the net profit attributable to shareholders of the parent company in the consolidated statement of the company in 2020 was ,584,420, 195.33 yuan; The net profit of the parent company's accounting statement 421,557,349.00 yuan. According to the parent company's current net profit as the base, extract 10% statutory provident fund 42,155,734.90 yuan, plus undistributed profit 1,152,229,187.97 yuan at the beginning of the year, minus 2019 annual cash dividend 103,225,148.40 yuan, and the distributable profit for this year is 1,428,405,653.67 yuan.
Company plans to make cash distribution in 2020 . Based on 2020 year-end share capital 344,083,828 shares, cash dividend 4.0 yuan (tax included) will be distributed for every 10 shares, and the total cash dividend will be distributed to all shareholders registered on the equity registration date is 137,633,531.20 yuan (tax included).
2020 No provident fund conversion to share capital.
If the total share capital of the company changes due to the conversion of convertible bonds/ repurchase of shares / equity incentive grant of share repurchase and cancellation / major asset restructuring share repurchase and cancellation during the period from the date of disclosure of this announcement to the date of registration of equity distribution, the company plans to maintain the distribution ratio per share unchanged and adjust the total distribution accordingly. If the subsequent total share capital changes, the specific adjustment will be announced separately.
This profit distribution plan still needs to be submitted to the general meeting of shareholders for consideration. In order to take into account the short-term income of shareholders and the long-term development of the company and maintain the continuity and relative stability of dividends, the board of directors put forward the above-mentioned profit distribution plan for 2020
. During the reporting period, the net profit attributable to shareholders of the listed company in the consolidated statement of the company was584,420,195.33
yuan, and the total cash dividend to be distributed was137,633,531.20 yuan (including tax), accounting for 23.55% of the net profit attributable to shareholders of listed companies this year, lower than 30% . The specific reasons are as follows: At present, the company is in the stage of accelerated development. In 2021 , the company will continue to promote the annual output of 20
.2 billion solid preparation project in Jinxi production base of peak pharmaceutical industry. New Peak North Carolina (formerly Anhui Zhongwang) Phase II Technological Transformation Project; The construction and transformation of projects under construction such as the New North Card Chemical Technology Transformation Project. In addition, Spike Pharmaceuticals and its subsidiaries have a number of new drugs in various stages of research and development, anti-tumor drugsDPT and JFAN-1001 have entered the clinical stage, Spike Pharmaceuticals and its subsidiaries Zhejiang Erying, Spike Yien will further increase product research and development and introduction efforts, the need to increase investment in research and development. In addition, the company will continue to seek other development projects in cement and medicine. The development of the above-mentioned business requires large financial support. 3. the decision-making procedure performed by the company (I) the convening, deliberation and voting of the board meeting
2021
# April24
, the company held the 108 meeting of the 11th board of directors#. the company currently has nine directors, all of whom attended the meeting, comply with the relevant provisions of the "Company Law" and the "Articles of Association", and the resolutions made are legal and valid. The meeting was presided over by Chairman Jiang Xiaomeng. After deliberation and voting, the profit distribution plan of the company 2020 was deliberated and approved by 110 votes, 0 votes against, and 0 votes abstention. The board of directors of intends to submit the plan to the annual general meeting of shareholders of 2020 for deliberation. When the company holds the general meeting of shareholders, it will provide investors with convenient conditions for online voting. (II) Opinions of Independent Directors
Independent Directors of the Company express the following opinions on the profit distribution plan of the Company2020 :
1
. We agree that the Company will distribute cash dividends4.0 yuan (including tax) for every 10 shares of the Company
2020year-end share capital ,344,083, 828 shares as the base, the total amount of cash dividends distributed to all shareholders registered on the date of record is ,633,531.20 yuan (including tax). 2020 year will not carry out provident fund to increase the share capital. 2 , the profit distribution plan is based on the actual operating results and financial situation of the company 2020 , combined with the actual needs of the company's future business development. Retained undistributed profits are mainly used to meet the capital needs of the company's development, which is conducive to the sustainable and healthy development of the company, and there is no harm to the rights and interests of shareholders, especially small and medium shareholders. The independent directors are of the opinion that the profit distribution plan complies with the relevant provisions of the Articles of Association for profit distribution and the actual operating conditions of the Company. 3
, the company's board of directors considered and approved the above profit distribution plan. The Independent Directors are of the opinion that the convening, holding and deliberation and voting procedures of this meeting are in compliance with relevant laws, regulations and the Articles of Association of the Company, and are legal and effective; and agree to submit the proposal to the Company's2020 Annual General Meeting for consideration. (III) the opinions of the board of supervisors
2021 July
24, the company held the 161 meeting of the 10th board of supervisors
2#. the company currently has five supervisors, all of whom attended the meeting in person, in line with the relevant provisions of the company law and the articles of association of the company, and the resolution made is legal and valid. The meeting was presided over by Mr. Chen Tianci, Chairman of the Board of Supervisors. After deliberation and voting, the company's profit distribution plan for the year2020 was deliberated and approved by 5 votes, 0 votes against, and 0 abstentions. Agree to submit to the general meeting of shareholders for consideration. The Board of Supervisors believes that: the company's 2020 profit distribution plan complies with the relevant provisions of the Articles of Association; the description of the profit distribution plan is objective and true, the decision-making procedures are in compliance, and meet the interests of all shareholders and the company's production and operation needs; The company's profit distribution and cash dividend decisions were not found to damage the legitimate rights and interests of shareholders. 4. Related Risk Reminder This profit distribution plan must be submitted to the company's 2020
annual general meeting for deliberation and approval before implementation. Investors are kindly requested to pay attention to investment risks.hereby announce
Zhejiang Jianfeng Group Co., Ltd.Dong
Affairs
MeetingApril
27, 2001
More information
Pharmaceutical Company Established New Drug R & D Promotion Committee
Recently, the new drug research and development promotion committee of Jianfeng pharmaceutical company was formally established, which will be responsible for promoting the new drug research and development progress of pharmaceutical companies and subordinate enterprises, and coordinating the new drug research and development work of various departments and subordinate enterprises. The New Drug Promotion Committee is headed by Huang Jinlong, deputy general manager of the group and general manager of the pharmaceutical company, and Jiang Hong, deputy general manager of the pharmaceutical company, is headed by Pang Xiong, Shi Cunyuan, Xu Lizhen, Yu Jingjing, Zheng Kunwu, Feng Lixiang, Kang Litao, Li Qian, Wu Chonggui, Zhai Tsunami, Huang Fang and Tong Xiaojun. The committee has an office, and Shi Cunyuan is also the director of the office, responsible for the supervision, communication, and coordination of the company's new drug research and development projects. The main responsibilities of the new drug promotion committee include: organizing the establishment and improvement of the R & D project management system and relevant regulations of the pharmaceutical company; organizing the formulation of the development plan of the new drug R & D project of the pharmaceutical company and supervising the implementation; making decisions on project initiation and participating in project evaluation; supervising the management of new drug R & D of the pharmaceutical company and providing guidance; Responsible for the process management of new drug R & D projects and the promotion and coordination of new drug R & D; carry out the assessment of new drug research and development projects; issue the responsibility system assessment and task statement of new drug research and development projects; be responsible for solving major technical problems in the process of new drug research and development; be responsible for the research and improvement of the management mode of research and development projects of pharmaceutical companies; be responsible for the future trend analysis of new drug research and development projects; review the major scientific research achievements of pharmaceutical companies and put forward reward suggestions. Huang Jinlong said that the research and development of new drugs is an important foundation for the healthy development of the pharmaceutical industry and is a systematic project. Jianfeng Pharmaceutical has always attached great importance to the research and development of new drugs, but there is still a certain gap between the progress of research and development and the development process of the enterprise, and the lack of coordination in the research and development process also affects the progress and quality of new drug research and development to a certain extent. The purpose of the establishment of the New Drug Research and Development Promotion Committee is to solve the progress of new drug research and development, to find and solve problems in time, to implement more targeted, and to effectively integrate enterprise resources, improve the speed and quality of new drug research and development, and make good product reserves for the healthy development of pharmaceutical companies. (Reporter Ni Yingzhen)
2020
09-11
Jianfeng Pharmaceutical ranks among the top 100 Chinese pharmaceutical industries in 2019
On August 25, the "2019 Top 100 Series List of China's Pharmaceutical Industry" was released in Kunming. Zhejiang Jianfeng Pharmaceutical Company was shortlisted as one of the top 100 enterprises in China's pharmaceutical industry. The product Berunning (Olopatadine Hydrochloride Eye Drops) was selected as the "Most Growing Product Brand" of China's pharmaceutical industry ". The "Top 100 Pharmaceutical Industry Series List" was evaluated and released by Guangzhou Punctuation Pharmaceutical Information Co., Ltd., a subsidiary of the Southern Institute of Pharmaceutical Economics of the State Drug Administration, and is known as the "Oscar in Chinese Pharmaceutical Industry. Southern Institute is the earliest institution in China that specializes in pharmaceutical industry policy and market economy research, pharmaceutical market research, pharmaceutical economic data analysis and research, and pharmaceutical professional media publishing. It is in the field of market information value-added services and media communication and marketing services in China's pharmaceutical and health industry., The field of professional quality improvement has extremely extensive influence. The "Top 100 Pharmaceutical Industry" is comprehensively evaluated by the company's annual pharmaceutical industry sales revenue, total profit and R & D investment results. On the same day, the "most growing product brand" of Chinese medicine selected by the Southern Institute's media "Pharmaceutical Economic News" was released simultaneously. Spike Pharmaceuticals product Beirunning (Olopatadine Hydrochloride Eye Drops) was selected. (Xu Yuting)
2020
09-01
Company Disclosure 2020 Semi-Annual Report
On August 28, the Group held the 16th meeting of the 10th Board of Directors of the Company by means of communication, and considered and adopted the "2020 Semi-Annual Report of Jianfeng Group" and the "Proposal on Changes in the Company's Accounting Policy". On August 29, the Company's 2020 semi-annual report was publicly disclosed on the Shanghai Stock Exchange and the Shanghai Securities News and China Securities News. In the first half of the year, the Group focused on the general policy of "grasping projects, making up for shortcomings, improving quality and efficiency, and constantly improving the core competitive advantage", and on the basis of doing a good job in epidemic prevention and control, the Group seized the resumption of work and production, accelerated project construction, and enhanced the core competitiveness of enterprises. In the first half of 2020, the company achieved total operating income of 1.44 billion yuan, net profit attributable to shareholders of 0.368 billion yuan, net profit per share of 1.07 yuan. As of the end of June 2020, the Company's total assets were $5.892 billion, net assets were $4.068 billion, and net assets per share were $11.82. From February to April, affected by the epidemic, the national project construction progress slowed down, cement market demand decreased; after May, the epidemic was effectively controlled, infrastructure investment continued to recover, the real estate industry continued to pick up, cement sales steadily rebounded. During the outbreak, Daye Peak completed the technical transformation projects such as the cold machine, cement mill, into the desulfurization tower anti-corrosion transformation, to ensure the efficient operation of the production equipment after the resumption of work. Yunnan peak rotary kiln production, cement production and other major technical and economic indicators of steady rise; comply with market trends, timely adjustment of marketing policies. Guizhou Jianfeng has promoted the project infrastructure construction, equipment installation and commissioning, raw material bidding and other work in an orderly manner, and through preliminary publicity to enhance the popularity of the Jianfeng brand in the local area, and make a series of preparations for the transformation from project construction to production and operation. In the first half of 2020, the reform of China's medical and health system continued to deepen, and new policies were introduced intensively. Peak Pharmaceuticals and its subsidiaries in the epidemic prevention work at the same time in the first time to achieve the resumption of production, and actively organize donations to support the fight against the epidemic, was named the annual "war epidemic star" the most socially responsible pharmaceutical enterprises. In the first half of the year, Jianfeng Pharmaceutical continued to increase the introduction and development of varieties, and JFAN-1001 applied for clinical application of new anti-tumor drugs. At present, it has obtained the notice of approval for clinical trials. Optimize the production process of API workshop and further shorten the production cycle of raw materials. Continue to improve product sales policies and strengthen market channel control. Shanghai North Carolina further straightened out the internal management structure, production and marketing convergence more smoothly, continue to promote the construction of Anhui North Carolina and Anhui Zhongwang Phase II technical transformation project, promote the peak pharmaceutical raw materials, preparations integration of industrial upgrading strategy. Other business segments of the company actively responded to the challenge of the new crown epidemic and carried out production and operation activities in a standardized and orderly manner. Tianjin natural products company vigorously explore the international and domestic markets, sales revenue to achieve steady growth. Peak Health focuses on the basic idea of "sales orientation, burden reduction and efficiency improvement, fine-grained savings, cost reduction and efficiency enhancement" to effectively improve the operational efficiency of enterprises. Jianfeng International Trade has actively developed new storage business varieties and achieved practical results, and has become the first enterprise in Jinhua to formally obtain the qualification of "network freight. Peak cable seizes the special needs of communication cables such as subways, vigorously promotes large logarithmic cables for subways, and strives to achieve the long tail effect. On the same day, the company also held the 10th meeting of the Ninth Board of Supervisors and reviewed and approved relevant reports. (residual fruit)
2020
09-01
The company organizes new employee induction training
From August 12 to 14, in order to strengthen the training of talents in the group and improve the comprehensive quality of new employees, Jiang Xiaomeng, secretary of the party committee and chairman of the group company, Yu Jianhong, general manager, and other leaders and heads of relevant enterprises and departments conducted a three-day induction training for new employees. New employees from foreign enterprises such as Guizhou Huangping Peak, Daye Peak and Shanghai North Carolina participated simultaneously through online methods. In the course of corporate culture, General Manager Yu Jianhong started from the history of the development and struggle of the peak, divided into five stages: hard work, determined reform, diversified development, strategic adjustment, and strategic development, and introduced in detail the development process of the group company and the current industrial layout., The results achieved; from the aspects of enterprise spirit, vision, development philosophy, values, business philosophy, etc, this paper introduces the peak corporate culture rooted in 62 years of history and inherited in the blood; from the perspective of an enterprise manager and old employees, he speaks a lot of truth to the new employees and puts forward a lot of hopes and suggestions. Chairman Jiang Xiaomeng took "How New Employees Achieve Win-Win with Enterprises" as the topic, and proposed that the key to the success of an enterprise lies in how to select, retain, educate and employ people. Peak and employees complement each other. Peak can achieve today's achievements and the struggle of generations of peak people are inseparable. He also taught new employees the basic concepts that need to be understood, the basic qualities that need to be possessed and the sense of hardship in entering the new environment through 16 key words, and combined with his own experience and quoting from others, he analyzed the core elements of success, the signs of a successful career, the personal qualities that need to be possessed for success, and the importance of establishing a personal knowledge management system, it expresses the ardent hope of new employees to adjust their mentality, keep learning, clear goals, clear dreams, cultivate win-win thinking, and grow up together with the peak. The heads of the human resources department of the group company, the safety management office of the group company, and the comprehensive department of the pharmaceutical company also taught the new employees the corporate rules and regulations and the "Employee Handbook", safety knowledge and professional ethics. The new employees also visited the group exhibition hall and had a deeper understanding of the development history and enterprise achievements of the peak. After the training, the human resources department also organized an examination to test the training effect. (Reporter Chen Shengmu)
2020
08-21
According to this newspaper, through the interconnection monitoring of the transportation department in Zhejiang province, the network freight platform of peak international trading company passed the online service capability audit, interface access audit, eight capability identification and other audit procedures, and successfully obtained the road transportation business license with the qualification of "network freight" on July 2. It is understood that Jianfeng International Trade is currently the first enterprise in Jinhua and Quzhou to obtain this qualification.
2020
08-05
News from our newspaper On July 21, Xi Jinping, General Secretary of the Central Committee of the Communist Party of China, President of the State, and Chairman of the Central Military Commission hosted a symposium for entrepreneurs in Beijing and delivered an important speech. Over the past few days, the General Secretary's speech has aroused strong repercussions in all walks of life. On July 23, Jiang Xiaomeng, chairman of the group company, said in an interview with Jinhua TV that the general secretary's speech was calm and inspiring, and pointed out the direction of future work for entrepreneurs.
2020
08-05